Firstpost
  • Home
  • Video Shows
    Vantage Firstpost America Firstpost Africa First Sports
  • World
    US News
  • Explainers
  • News
    India Opinion Cricket Tech Entertainment Sports Health Photostories
  • Asia Cup 2025
Apple Incorporated Modi ji Justin Trudeau Trending

Sections

  • Home
  • Live TV
  • Videos
  • Shows
  • World
  • India
  • Explainers
  • Opinion
  • Sports
  • Cricket
  • Health
  • Tech/Auto
  • Entertainment
  • Web Stories
  • Business
  • Impact Shorts

Shows

  • Vantage
  • Firstpost America
  • Firstpost Africa
  • First Sports
  • Fast and Factual
  • Between The Lines
  • Flashback
  • Live TV

Events

  • Raisina Dialogue
  • Independence Day
  • Champions Trophy
  • Delhi Elections 2025
  • Budget 2025
  • US Elections 2024
  • Firstpost Defence Summit
Trending:
  • Nepal protests
  • Nepal Protests Live
  • Vice-presidential elections
  • iPhone 17
  • IND vs PAK cricket
  • Israel-Hamas war
fp-logo
Gilead to challenge hepatitis C drug patent rejection
Whatsapp Facebook Twitter
Whatsapp Facebook Twitter
Apple Incorporated Modi ji Justin Trudeau Trending

Sections

  • Home
  • Live TV
  • Videos
  • Shows
  • World
  • India
  • Explainers
  • Opinion
  • Sports
  • Cricket
  • Health
  • Tech/Auto
  • Entertainment
  • Web Stories
  • Business
  • Impact Shorts

Shows

  • Vantage
  • Firstpost America
  • Firstpost Africa
  • First Sports
  • Fast and Factual
  • Between The Lines
  • Flashback
  • Live TV

Events

  • Raisina Dialogue
  • Independence Day
  • Champions Trophy
  • Delhi Elections 2025
  • Budget 2025
  • US Elections 2024
  • Firstpost Defence Summit
  • Home
  • Business
  • Gilead to challenge hepatitis C drug patent rejection

Gilead to challenge hepatitis C drug patent rejection

FP Archives • January 16, 2015, 14:28:20 IST
Whatsapp Facebook Twitter

An order by deputy controller of patents and designs Hardev Karar has said Gilead, which sells the drug under the Sovaldi brand in the US, failed to prove that there were enhancement of therapeutic efficacy in the new discovery.

Advertisement
Subscribe Join Us
Add as a preferred source on Google
Prefer
Firstpost
On
Google
Gilead to challenge hepatitis C drug patent rejection

New Delhi: Gilead Sciences Inc will appeal against the decision of the Indian Patent Office rejecting its patent application for hepatitis C drug sofosbuvir. “Gilead strongly defends its intellectual property. The company will be appealing the decision as well as exploring additional procedural options,” Gilead Sciences Corporate and Medical Affairs, executive vice president, Gregg Alton said. [caption id=“attachment_2050135” align=“alignleft” width=“380”] ![Representational image. Reuters](https://images.firstpost.com/wp-content/uploads/2015/01/capsule380.jpg) Representational image. Reuters[/caption] This rejection relates to the patent application covering the metabolites of sofosbuvir. Gilead is pleased that the Patent Office found in favour of the novelty and inventiveness of its claims, but believes their Section 3(d) decision to be improper, he said. “The main patent applications covering sofosbuvir are still pending before the Indian Patent Office,” Alton said. These proceedings do not impact the company’s commitment to enabling access to its hepatitis C medicines in India and other developing countries, and its generic licensing programme with its Indian partners continues as normal, he said. An order by deputy controller of patents and designs Hardev Karar has said Gilead, which sells the drug under the Sovaldi brand in the US, failed to prove that there were enhancement of therapeutic efficacy in the new discovery. Gilead’s patent application was opposed by Hyderabad-based Natco Pharma and Capital-based NGO Delhi Network of Positive People (DNP+). Another entity Initiative for Medicines, Access & Knowledge {1-MAK), Inc, USA had also opposed it. Gilead had last year entered into licensing agreements with seven India-based firms, including Cipla, Ranbaxy and Cadila for the hepatitis C drugs to make them available in 91 developing countries. Gilead had said it planned to launch its own branded Sovaldi in India at a price of $300 per bottle, while the Indian companies were allowed to fix their own price for the generic product they produce, paying a royalty on sales. As per reports, Sovaldi was priced $84,000 for a 12-week course in the US which has been criticised by advocates of patients. When contacted Natco Pharma officials declined to comment on the development. PTI

Tags
Cadila Health Cipla CompanyWatch Ranbaxy Gilead Sciences Natco Pharma hepatitis C Sofosbuvir
End of Article
Written by FP Archives

see more

Latest News
Find us on YouTube
Subscribe
End of Article

Impact Shorts

Tata Harrier EV vs Mahindra XEV 9e: Design and road presence compared

Tata Harrier EV vs Mahindra XEV 9e: Design and road presence compared

The Tata Harrier EV and Mahindra XEV 9e are new electric SUVs in India. The Harrier EV has a modern, familiar design, while the XEV 9e features a bold, striking look. They cater to different preferences: the Harrier EV for subtle elegance and the XEV 9e for expressive ruggedness.

More Impact Shorts

Top Stories

Israel targets top Hamas leaders in Doha; Qatar, Iran condemn strike as violation of sovereignty

Israel targets top Hamas leaders in Doha; Qatar, Iran condemn strike as violation of sovereignty

Nepal: Oli to continue until new PM is sworn in, nation on edge as all branches of govt torched

Nepal: Oli to continue until new PM is sworn in, nation on edge as all branches of govt torched

Who is CP Radhakrishnan, India's next vice-president?

Who is CP Radhakrishnan, India's next vice-president?

Israel informed US ahead of strikes on Hamas leaders in Doha, says White House

Israel informed US ahead of strikes on Hamas leaders in Doha, says White House

Israel targets top Hamas leaders in Doha; Qatar, Iran condemn strike as violation of sovereignty

Israel targets top Hamas leaders in Doha; Qatar, Iran condemn strike as violation of sovereignty

Nepal: Oli to continue until new PM is sworn in, nation on edge as all branches of govt torched

Nepal: Oli to continue until new PM is sworn in, nation on edge as all branches of govt torched

Who is CP Radhakrishnan, India's next vice-president?

Who is CP Radhakrishnan, India's next vice-president?

Israel informed US ahead of strikes on Hamas leaders in Doha, says White House

Israel informed US ahead of strikes on Hamas leaders in Doha, says White House

Top Shows

Vantage Firstpost America Firstpost Africa First Sports
Latest News About Firstpost
Most Searched Categories
  • Web Stories
  • World
  • India
  • Explainers
  • Opinion
  • Sports
  • Cricket
  • Tech/Auto
  • Entertainment
  • IPL 2025
NETWORK18 SITES
  • News18
  • Money Control
  • CNBC TV18
  • Forbes India
  • Advertise with us
  • Sitemap
Firstpost Logo

is on YouTube

Subscribe Now

Copyright @ 2024. Firstpost - All Rights Reserved

About Us Contact Us Privacy Policy Cookie Policy Terms Of Use
Home Video Shorts Live TV